Incyte Corp. Common Stock INCY
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-08T09:15:32.925Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T23:46:37.575449024Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-08T09:10:26.943568+00:00
Incyte Corp. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 131.88 | 56.2% | 11.0% | 110.37 | 58.1% | 9.3% |
| 25Δ | 129.68 | 57.7% | 9.6% | 112.62 | 54.9% | 7.7% |
| 30Δ | 127.77 | 57.7% | 8.4% | 114.87 | 51.7% | 6.2% |
| 35Δ | 125.86 | 57.7% | 7.2% | 116.35 | 50.8% | 5.4% |
| 40Δ | 124.09 | 56.4% | 6.2% | 117.79 | 50.0% | 4.6% |
| 45Δ | 122.44 | 54.0% | 5.2% | 119.23 | 49.2% | 3.9% |
| 50Δ | 120.79 | 51.6% | 4.2% | 120.78 | 50.1% | 3.3% |
| 55Δ | 119.34 | 49.6% | 3.4% | 122.44 | 53.2% | 3.0% |
| 60Δ | 118.08 | 47.9% | 2.9% | 124.09 | 56.2% | 2.6% |
| 65Δ | 116.83 | 46.3% | 2.3% | 125.75 | 57.2% | 2.2% |
| 70Δ | 115.57 | 44.6% | 1.8% | 127.41 | 55.7% | 1.8% |
| 75Δ | 114.17 | 43.5% | 1.4% | 129.07 | 54.2% | 1.3% |
| 80Δ | 112.65 | 42.7% | 1.1% | 131.39 | 54.5% | 0.9% |
20Δ
- Pseudo strike
- 131.88
- IV
- 56.2%
- B/E move
- 11.0%
- Pseudo strike
- 110.37
- IV
- 58.1%
- B/E move
- 9.3%
25Δ
- Pseudo strike
- 129.68
- IV
- 57.7%
- B/E move
- 9.6%
- Pseudo strike
- 112.62
- IV
- 54.9%
- B/E move
- 7.7%
30Δ
- Pseudo strike
- 127.77
- IV
- 57.7%
- B/E move
- 8.4%
- Pseudo strike
- 114.87
- IV
- 51.7%
- B/E move
- 6.2%
35Δ
- Pseudo strike
- 125.86
- IV
- 57.7%
- B/E move
- 7.2%
- Pseudo strike
- 116.35
- IV
- 50.8%
- B/E move
- 5.4%
40Δ
- Pseudo strike
- 124.09
- IV
- 56.4%
- B/E move
- 6.2%
- Pseudo strike
- 117.79
- IV
- 50.0%
- B/E move
- 4.6%
45Δ
- Pseudo strike
- 122.44
- IV
- 54.0%
- B/E move
- 5.2%
- Pseudo strike
- 119.23
- IV
- 49.2%
- B/E move
- 3.9%
50Δ
- Pseudo strike
- 120.79
- IV
- 51.6%
- B/E move
- 4.2%
- Pseudo strike
- 120.78
- IV
- 50.1%
- B/E move
- 3.3%
55Δ
- Pseudo strike
- 119.34
- IV
- 49.6%
- B/E move
- 3.4%
- Pseudo strike
- 122.44
- IV
- 53.2%
- B/E move
- 3.0%
60Δ
- Pseudo strike
- 118.08
- IV
- 47.9%
- B/E move
- 2.9%
- Pseudo strike
- 124.09
- IV
- 56.2%
- B/E move
- 2.6%
65Δ
- Pseudo strike
- 116.83
- IV
- 46.3%
- B/E move
- 2.3%
- Pseudo strike
- 125.75
- IV
- 57.2%
- B/E move
- 2.2%
70Δ
- Pseudo strike
- 115.57
- IV
- 44.6%
- B/E move
- 1.8%
- Pseudo strike
- 127.41
- IV
- 55.7%
- B/E move
- 1.8%
75Δ
- Pseudo strike
- 114.17
- IV
- 43.5%
- B/E move
- 1.4%
- Pseudo strike
- 129.07
- IV
- 54.2%
- B/E move
- 1.3%
80Δ
- Pseudo strike
- 112.65
- IV
- 42.7%
- B/E move
- 1.1%
- Pseudo strike
- 131.39
- IV
- 54.5%
- B/E move
- 0.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 35.26% | |
| 35.93% | |
| 34.95% | |
| 34.90% | |
| 36.37% | |
| 36.63% | |
| 39.38% | |
| 35.63% | |
| 36.60% | |
| 35.47% | |
| 34.81% | |
| 35.86% | |
| 36.47% | |
| 37.72% | |
| 36.30% | |
| 35.38% | |
| 36.03% | |
| 36.07% | |
| 37.69% | |
| 36.59% | |
| 37.71% | |
| 37.20% | |
| 38.73% | |
| 43.73% | |
| 40.15% | |
| 40.65% | |
| 38.00% | |
| 40.43% | |
| 40.11% | |
| 38.51% | |
| 41.45% | |
| 42.64% | |
| 41.23% | |
| 41.06% | |
| 42.07% | |
| 41.27% | |
| 43.07% | |
| 43.46% | |
| 42.93% | |
| 43.29% | |
| 43.45% | |
| 48.83% | |
| 47.90% | |
| 51.89% | |
| 52.92% | |
| 42.70% | |
| 42.46% | |
| 43.05% | |
| 44.95% | |
| 44.53% | |
| 43.98% | |
| 41.12% | |
| 40.18% | |
| 40.89% | |
| 36.68% | |
| 36.79% |
Biotechnology
INMB
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic…
More →INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases…
More →INSM
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New…
More →INVA
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
More →IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
More →IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's…
More →